CRME Key Stats
- Cardiome Pharma Management Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 13
- Cardiome Reports First Quarter Results CNW Group May 13
- Earnings Scheduled For May 13, 2013 Benzinga May 13
- Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference CNW Group May 10
- Cardiome to Hold First Quarter 2013 Financial Results Conference Call on May 13 CNW Group May 9
- Cardiome Accepts the Transfer of Sponsorship of U.S. and Canadian Vernakalant IV... May 2
- Cardiome Announces Worldwide Sales And Marketing Of BRINAVESS noodls Apr 25
- Cardiome Pharma Announces Marketing Pact with Merck for Brinavess Benzinga Apr 25
- Cardiome Announces Worldwide Sales And Marketing Of BRINAVESS™ CNW Group Apr 25
- Cardiome Announces Share Consolidation Effective April 12, 2013 noodls Apr 12
CRME Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Cardiome Pharma Corporation is down 3.70% over the last year vs S&P 500 Total Return up 27.96%, Merrimack Pharmaceuticals down 20.97%, and Chemocentryx up 15.79%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CRME
Pro Report PDF for CRME
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CRME Pro Report PDF
Pro Strategies Featuring CRME
Did Cardiome Pharma Corporation make it into our Pro Portfolio Strategies?